Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
about
Immune checkpoint blockade therapy for bladder cancer treatmentViro-immune therapy: A new strategy for treatment of pancreatic cancerImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectDrosophila at the intersection of infection, inflammation, and cancerWhich Metrics Are Appropriate to Describe the Value of New Cancer Therapies?The Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentPrioritizing therapeutic targets using patient-derived xenograft modelsInflammation and the two-hit hypothesis of schizophrenia.Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination.M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cellsUsing Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.Gene Electrotransfer of Plasmid-Encoding IL-12 Recruits the M1 Macrophages and Antigen-Presenting Cells Inducing the Eradication of Aggressive B16F10 Murine Melanoma.Comparative Gene Expression Analysis of Lymphocytes Treated with Exosomes Derived from Ovarian Cancer and Ovarian Cysts.Distinct Blood and Visceral Adipose Tissue Regulatory T Cell and Innate Lymphocyte Profiles Characterize Obesity and Colorectal Cancer.Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation.RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care unitsA novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase.Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.Human cell-based artificial antigen-presenting cells for cancer immunotherapy.TroVax in colorectal cancerRisk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort studyMesenchymal stem cells are enriched in head neck squamous cell carcinoma, correlates with tumour size and inhibit T-cell proliferation.API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignanciesGalectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients.Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer modelDevelopment of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults.Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategiesImmune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcomaSafety and Efficacy of Transplantation with Allogeneic Skin Tumors to Treat Chemically-Induced Skin Tumors in MiceEffect of Th1/Th2 cytokine administration on proinflammatory SKOV-3 cell activation.The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma.Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
P2860
Q26744139-1D154E9E-6434-4DF5-A78F-C5D3393C4A62Q26774641-815D7057-0E39-49C8-9ACF-B28587482412Q26781538-F24C077F-D875-413D-9C37-5E13404E6F82Q26826830-A269DC99-B652-4704-B692-106853831854Q26827570-7D41359E-D3CB-47E7-BD37-C2E3C063F61FQ26858853-B27807FE-C784-4914-AAC8-326DD4B0C374Q27022789-15E9348A-69EB-4C1D-BD3E-7BCA2CBC9607Q28083993-B3DAA50C-5287-44BF-BCDD-1C995876E0CAQ30422062-BFCE5406-A25A-4B95-8F20-904559F2EB0AQ33577585-9D52AB39-275B-45DE-9836-E1DC09B77062Q33591540-2BAF0C8E-772D-4BD2-9C3F-7867D59240BFQ33621881-1512039C-6DF8-4273-85AB-9A91196EB6E9Q33741348-5D643386-63F6-475E-BB7C-861FAFE74001Q33747629-51D983B7-849A-4EDE-8AED-676012AB6752Q33780586-94358FE3-3C09-4A60-8373-36A3F388EFA6Q33786891-2482440F-261D-49C9-B425-DA591DBD598AQ33826424-62ED2653-29C6-4CE9-A8F9-53CBF72F2E4CQ33888114-64842076-D7B0-4725-ABD8-6FBEA1BD8C0BQ34184578-7775362C-4330-43EA-BF53-924003EDD7C3Q34259974-E10646EF-0DCB-496D-9B3B-F81109321329Q34391263-2AA2C8C0-99B8-4769-B20F-676B4C8DAD5FQ34452474-146454B0-29DD-4B3B-8511-33B158DBC37AQ34695339-6378C9FE-A836-40AE-B633-A5C01C6254D2Q35098364-1495EAF0-92F7-425E-B538-1EDD87AF1872Q35386974-383580CD-AEC6-46A9-AFD8-6F846FC9D5C6Q35538728-159D9305-BBF0-4A34-A1D8-123805C958E5Q35931701-51B839FD-D104-4D32-AEDC-31E43DE35EF3Q35941343-6E80CDD9-B8B1-49DE-B5E3-A829BEE8D9B4Q35984198-6FF514B1-BEFD-472C-B6DB-8F0F907EBCEEQ36017810-165786C4-CCBE-4C83-9DF6-E21C5C74AE48Q36137504-A52A6ED1-9081-4592-B180-E6BC9409B24AQ36414022-82984075-3C23-4675-8077-0E6E2CBF650FQ36734451-B0ED6C1B-E262-417E-B9FF-4E8638962CE6Q36737701-EDCBD015-C0E0-4D18-9776-D9653A504313Q36951914-03E125C7-81F2-4D94-A05D-4CF39A77EBC5Q37125088-A17FA6BD-5389-4756-B4C3-18CDFD3963B4Q37248413-095DD44A-DA16-4B3B-9FB2-9AF3ECE73908Q37412635-D0EEC1AD-2A9C-4123-8C85-9AB0634833A2Q37507473-DC972B9C-89FA-45C3-8C36-2BABBD28669BQ37542216-5324B93D-C63C-4495-A115-0DA8931F3BA1
P2860
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Immuno-oncology: understanding ...... f the immune system in cancer.
@ast
Immuno-oncology: understanding ...... f the immune system in cancer.
@en
type
label
Immuno-oncology: understanding ...... f the immune system in cancer.
@ast
Immuno-oncology: understanding ...... f the immune system in cancer.
@en
prefLabel
Immuno-oncology: understanding ...... f the immune system in cancer.
@ast
Immuno-oncology: understanding ...... f the immune system in cancer.
@en
P2860
P356
P1433
P1476
Immuno-oncology: understanding ...... f the immune system in cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDS256
P478
23 Suppl 8
P577
2012-09-01T00:00:00Z